NCT01290094

A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis

Interventional, Single Arm, Open Label Study of the Efficacy, Safety and Compliance to the Treatment With Intravenous (IV) Ibandronate (Bonviva®) in the Postmenopausal Osteoporosis Treatment of Bisphosphonates naïve Patients in Daily Practice

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: Female
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg intravenously every three months. Anticipated time on study treatment is 12 months with a follow-up of 12 months.

Conditions

• Post Menopausal Osteoporosis

Interventions

Type	Name	Description
DRUG	ibandronate [Bonviva/Boniva]	3 mg intravenously every 3 months

Timeline

• Start date: 2011-04-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2011-02-04
• Last updated: 2015-08-13
• Results posted: 2015-08-13

Locations

2 sites across 1 country: Bosnia and Herzegovina